In the News

Organoids Touted as Future of Brain Disorder R&D as AxoSim Scoops Up Tech from Vyant Subsidiary

October 24, 2023
Loading the Elevenlabs Text to Speech AudioNative Player...
As Vyant Bio continues its wind-down, the neuroscience research assets of its subsidiary StemoniX have officially been picked up by AxoSim, a New Orleans-based drug discovery biotech.

Related Stories

Spotlight
5/7/2026
28bioGRANT for Neurodegenerative Disease Awardees Announced
28bio announces the 2026 recipients of the 28bioGRANT for Neurodegenerative Disease, supporting innovative research in CNS-targeted nanotherapeutics and human iPSC-based Alzheimer’s disease modeling.
In the News
3/23/2026
28bio’s Endurance Study Meets Primary Endpoint, Showing CNS-3D Brain Organoids Predict Clinical Seizure Liability
Spotlight
3/2/2026
28bioGRANT for Neurodegenerative Disease
The 28bioGRANT for Neurodegenerative Disease is designed to assist academic researchers in their pursuit to understand the human biological underpinnings of these diseases and translate those insights into potential therapeutic strategies.
Join our mailing list.
Thank you! Your submission has been received.
Something went wrong while submitting the form.
© 2025 28bio. All rights reserved.
Privacy Policy
Terms of Use
FCOI Polcy